{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:57:57Z","timestamp":1790909877058,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.clml.2021.12.018","type":"journal-article","created":{"date-parts":[[2021,12,24]],"date-time":"2021-12-24T02:36:27Z","timestamp":1640313387000},"page":"474-482","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Inpatient treatment of relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL): A health economic perspective"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8643-4170","authenticated-orcid":false,"given":"Bernhard","family":"Moertl","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Dreyling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Hoster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Schoel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael v.","family":"Bergwelt-Baildon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2021.12.018_bib0001","unstructured":"Aitken, M., et\u00a0al., Global Oncology Trends 2019. IQVIA Institute for Human Data Science, Parsippany, 2019 Therapeutics, clinical development and health system implications."},{"key":"10.1016\/j.clml.2021.12.018_bib0002","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMp1011024","article-title":"What is value in health care?","volume":"363","author":"Porter","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.12.018_bib0003","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/j.drudis.2018.09.002","article-title":"The future of drug development: the paradigm shift towards systems therapeutics","volume":"23","author":"Danhof","year":"2018","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.clml.2021.12.018_bib0004","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.zefq.2009.02.012","article-title":"Prioritisation in health care: learning from international experiences","volume":"103","author":"Marckmann","year":"2009","journal-title":"Z Evid Fortbild Qual Gesundhwes"},{"key":"10.1016\/j.clml.2021.12.018_bib0005","doi-asserted-by":"crossref","first-page":"3724","DOI":"10.1182\/blood-2010-05-282632","article-title":"Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project","volume":"116","author":"Sant","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.12.018_bib0006","series-title":"Bericht zum Krebsgeschehen in Deutschland 2016","author":"Barnes","year":"2017"},{"key":"10.1016\/j.clml.2021.12.018_bib0007","series-title":"Pr\u00e4valenz und des \u00dcberlebens von Krebs in Deutschland auf Basis der epidemiologischen Landeskrebsregisterdaten","article-title":"Datenbankabfrage mit Sch\u00e4tzung der Inzidenz, Pr\u00e4valenz und des \u00dcberlebens von Krebs in Deutschland auf Basis der epidemiologischen Landeskrebsregisterdaten","author":"Zentrum f\u00fcr Krebsregisterdaten im Robert Koch-Institut","year":"2021"},{"key":"10.1016\/j.clml.2021.12.018_bib0008","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.25460","article-title":"Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment","volume":"94","author":"Liu","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2021.12.018_bib0009","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1002\/cncr.23861","article-title":"Pretransplantation positron emission tomography scan is the main predictor of autologous stem cell transplantation outcome in aggressive B-cell non-Hodgkin lymphoma","volume":"113","author":"Derenzini","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2021.12.018_bib0010","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1148\/radiol.2015142556","article-title":"Prognostic Value of FDG PET\/CT before Allogeneic and Autologous Stem Cell Transplantation for Aggressive Lymphoma","volume":"277","author":"Ulaner","year":"2015","journal-title":"Radiology"},{"key":"10.1016\/j.clml.2021.12.018_bib0011","first-page":"1","article-title":"Diffuses gro\u00dfzelliges B-Zell-Lymphom","volume":"April","author":"Georg","year":"2021","journal-title":"Onkopedia Leitlinien"},{"key":"10.1016\/j.clml.2021.12.018_bib0012","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1182\/blood-2014-05-577189","article-title":"Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity","volume":"125","author":"Sehn","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.12.018_bib0013","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/14737167.2019.1680288","article-title":"Cost burden of diffuse large B-cell lymphoma","volume":"19","author":"Harkins","year":"2019","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.clml.2021.12.018_bib0014","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1634\/theoncologist.2014-0113","article-title":"Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medi care analysis","volume":"19","author":"Hamlin","year":"2014","journal-title":"The oncologist"},{"key":"10.1016\/j.clml.2021.12.018_bib0015","doi-asserted-by":"crossref","unstructured":"Delarue, R., et\u00a0al., R-CHOP14 compared to R-CHOP21 in elderly patients with diffuse large B-cell lymphoma (DLBCL): Final analysis of the LNH03-6B GELA study.2012. 30(15_suppl): p. 8021-8021.","DOI":"10.1200\/jco.2012.30.15_suppl.8021"},{"key":"10.1016\/j.clml.2021.12.018_bib0016","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","article-title":"Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favorable prognosis (FLYER): a randomized, phase 3, non-inferiority trial","volume":"394","author":"Poeschel","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2021.12.018_bib0017","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.beha.2018.07.014","article-title":"Management of relapsed\/refractory DLBCL","volume":"31","author":"Sarkozy","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"10.1016\/j.clml.2021.12.018_bib0018","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"10.1016\/j.clml.2021.12.018_bib0019","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/bjh.15412","article-title":"How I manage patients with relapsed\/refractory diffuse large B cell lymphoma","volume":"182","author":"Gisselbrecht","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2021.12.018_bib0020","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.12.018_bib0021","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.12.018_bib0022","doi-asserted-by":"crossref","first-page":"5118","DOI":"10.1182\/blood-2012-02-408773","article-title":"A phase 1 study of obinutuzumab induction followed by 2 years of maintenance in patients with relapsed CD20-positive B-cell malignancies","volume":"119","author":"Sehn","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.12.018_bib0023","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2021.12.018_bib0024","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the International CORAL study","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2021.12.018_bib0025","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2021.12.018_bib0026","unstructured":"European-medicines-agency, EPAR - Product Information - Kymriah. 2018, EMA."},{"key":"10.1016\/j.clml.2021.12.018_bib0027","unstructured":"European-medicines-agency, EPAR - Product information - Yescarta. 2018, EMA."},{"issue":"Suppl 1","key":"10.1016\/j.clml.2021.12.018_bib0028","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.4103\/sja.SJA_543_18","article-title":"The STROBE guidelines","volume":"13","author":"Cuschieri","year":"2019","journal-title":"Saudi J Anaesth"},{"key":"10.1016\/j.clml.2021.12.018_bib0029","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1007\/s00117-020-00676-4","article-title":"Hybridbildgebung bei Lymphom","volume":"60","author":"Mayerh\u00f6fer","year":"2020","journal-title":"Der Radiologe"},{"key":"10.1016\/j.clml.2021.12.018_bib0030","unstructured":"G-DRG Catalogue (aG-DRG-Fallpauschalen-Katalog) 2007 to 2021. Homepage of the InEK GmbH \u2013 Institut f\u00fcr das Entgeltsystem im Krankenhaus, www. g-drg.de, last access: 29.11.2021."},{"key":"10.1016\/j.clml.2021.12.018_bib0031","unstructured":"G-DRGHistory. Homepage of reimbursement.INFO (RI Innovation GmbH, H\u00fcrth) Link: https:\/\/app.reimbursement.info\/drgs, last access: 29.11.2021."},{"key":"10.1016\/j.clml.2021.12.018_bib0032","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1080\/10428194.2020.1734592","article-title":"The economic burden to payers of patients with diffuse large B-cell lymphoma during the treatment period by line of therapy","volume":"61","author":"Tkacz","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2021.12.018_bib0033","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3747\/co.26.4565","article-title":"Real-world costing analysis for diffuse large B-cell lymphoma in British Columbia","volume":"26","author":"Costa","year":"2019","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clml.2021.12.018_bib0034","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2217\/fon-2018-0788","article-title":"Evaluation of treatment patterns and survival among patients with diffuse large B-cell lymphoma in the USA","volume":"15","author":"Morrison","year":"2019","journal-title":"Future Oncol"},{"key":"10.1016\/j.clml.2021.12.018_bib0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0237509","article-title":"Nationwide claims database analysis of treatment patterns, costs and survival of Japanese patients with diffuse large B-cell lymphoma","volume":"15","author":"Tsutsu\u00e9","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2021.12.018_bib0036","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1634\/theoncologist.2018-0490","article-title":"Direct Costs Associated with Relapsed Diffuse Large B-Cell Lymphoma Therapies","volume":"24","author":"Purdum","year":"2019","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2021.12.018_bib0037","doi-asserted-by":"crossref","DOI":"10.1177\/0963689720975397","article-title":"Comparison of Survival Between Autologous and Allogeneic Stem Cell Transplantation in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: A Meta-Analysis","volume":"29","author":"Wang","year":"2020","journal-title":"Cell Transplantation"},{"key":"10.1016\/j.clml.2021.12.018_bib0038","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2021.12.018_bib0039","doi-asserted-by":"crossref","first-page":"402","DOI":"10.6004\/jnccn.2017.7065","article-title":"Medical Care Costs Associated With Cancer in Integrated Delivery Systems","volume":"16","author":"Banegas","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2021.12.018_bib0040","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1186\/1471-2407-14-586","article-title":"Real world costs and cost-effectiveness of Rituximab for diffuse large B-cell lymphoma patients: a population-based analysis","volume":"14","author":"Khor","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clml.2021.12.018_bib0041","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/j.1524-4733.2007.00227.x","article-title":"Costs associated with diffuse large B-cell lymphoma patient treatment in a Canadian integrated cancer care center","volume":"11","author":"Lee","year":"2008","journal-title":"Value Health"},{"key":"10.1016\/j.clml.2021.12.018_bib0042","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2217\/cer-2018-0100","article-title":"Cost associated with hematopoietic stem cell transplantation: a retrospective claims data analysis in Germany","volume":"8","author":"Mayerhoff","year":"2019","journal-title":"J Comp Eff Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502102485X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502102485X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T13:59:13Z","timestamp":1682949553000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502102485X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":42,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S215226502102485X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2021.12.018","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inpatient treatment of relapsed\/refractory diffuse large B-cell lymphoma (r\/r DLBCL): A health economic perspective","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2021.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}